[{"orgOrder":0,"company":"Population Health Research Institute ","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Population Health Research Institute ","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Population Health Research Institute \/ Bayer ","highestDevelopmentStatusID":"10","companyTruncated":"Population Health Research Institute \/ Bayer "}]

Find Clinical Drug Pipeline Developments & Deals for Interferon Beta 1B

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Population Health Research Institute

Country arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Population Health Research Institute

Country arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Bayer and PHRI together will conduct two studies that will evaluate the safety and efficacy of different combination therapies including Bayer’s chloroquine and interferon beta-1b.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Undisclosed

April 21, 2020

Lead Product(s) : Chloroquine Phosphate,Azithromycin,Interferon Beta 1B

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Sponsor : Bayer AG

Deal Size : $1.1 million

Deal Type : Partnership

blank